PUBLICATION
Lapatinib combined with doxorubicin causes dose-dependent cardiotoxicity partially through activating the p38MAPK signaling pathway in zebrafish embryos
- Authors
- Du, K., Liu, Y., Zhang, L., Peng, L., Dong, W., Jiang, Y., Niu, M., Sun, Y., Wu, C., Niu, Y., Ding, Y.
- ID
- ZDB-PUB-240424-16
- Date
- 2024
- Source
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 175: 116637116637 (Journal)
- Registered Authors
- Ding, Yonghe
- Keywords
- Cardiotoxicity, Doxorubicin, Lapatinib, P38MAPK signaling, Zebrafish embryos
- MeSH Terms
-
- Animals
- Cardiotoxicity*/etiology
- Dose-Response Relationship, Drug
- Doxorubicin*/adverse effects
- Doxorubicin*/toxicity
- Embryo, Nonmammalian/drug effects
- Female
- Lapatinib*/pharmacology
- MAP Kinase Signaling System*/drug effects
- Oxidative Stress/drug effects
- Zebrafish*/embryology
- p38 Mitogen-Activated Protein Kinases*/metabolism
- PubMed
- 38653111 Full text @ Biomed. Pharmacother.
Citation
Du, K., Liu, Y., Zhang, L., Peng, L., Dong, W., Jiang, Y., Niu, M., Sun, Y., Wu, C., Niu, Y., Ding, Y. (2024) Lapatinib combined with doxorubicin causes dose-dependent cardiotoxicity partially through activating the p38MAPK signaling pathway in zebrafish embryos. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 175:116637116637.
Abstract
Because of its enhanced antitumor efficacy, lapatinib (LAP) is commonly used clinically in combination with the anthracycline drug doxorubicin (DOX) to treat metastatic breast cancer. While it is well recognized that this combination chemotherapy can lead to an increased risk of cardiotoxicity in adult women, its potential cardiotoxicity in the fetus during pregnancy remains understudied. Here, we aimed to examine the combination of LAP chemotherapy and DOX-induced cardiotoxicity in the fetus using a zebrafish embryonic system and investigate the underlying pathologic mechanisms. First, we examined the dose-dependent cardiotoxicity of combined LAP and DOX exposure in zebrafish embryos, which mostly manifested as pericardial edema, bradycardia, cardiac function decline and reduced survival. Second, we revealed that a significant increase in oxidative stress concurrent with activated MAPK signaling, as indicated by increased protein expression of phosphorylated p38 and Jnk, was a notable pathophysiological event after combined LAP and DOX exposure. Third, we showed that inhibiting MAPK signaling by pharmacological treatment with the p38MAPK inhibitor SB203580 or genetic ablation of the map2k6 gene could significantly alleviate combined LAP and DOX exposure-induced cardiotoxicity. Thus, we provided both pharmacologic and genetic evidence to suggest that inhibiting MAPK signaling could exert cardioprotective effects. These findings have implications for understanding the potential cardiotoxicity induced by LAP and DOX combinational chemotherapy in the fetus during pregnancy, which could be leveraged for the development of new therapeutic strategies.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping